Videos
Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer
Findings From the Phase 1b/2 OrigAMI-1 Study
Findings From the Phase 1b/2 OrigAMI-1 Study
09/14/2024
Filippo Piertrantonio, MD, National Cancer Institute of Milan, Italy, discusses results from the OrigAMI-1 study. Results determined that amivantamab plus FOLFOX or FOLFIRI demonstrates antitumor activity and manageable safety in patients with RAS/RAF-wild type metastatic colorectal cancer (CRC).
Dr Pietrantonio presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Source:
Pietrantonio F, Ho GF, Su YL, et al. Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract 513MO